Sensex Today | AstraZeneca gets nod for sale of Durvalumab Solution
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) for an additional indication.
AstraZeneca Pharma was quoting at Rs 9,230.90, up Rs 46.30, or 0.50 percent.
It has touched an intraday high of Rs 9,649.60 and an intraday low of Rs 9,200.35.
It was trading with volumes of 3,781 shares, compared to its five day average of 1,606 shares, an increase of 135.40 percent.
In the previous trading session, the share closed down 0.57 percent or Rs 52.45 at Rs 9,184.60.
The share touched a 52-week high of Rs 10,653.05 and a 52-week low of Rs 6,222.35 on 13 June, 2025 and 21 November, 2024, respectively.
Currently, the stock is trading 13.35 percent below its 52-week high and 48.35 percent above its 52-week low.
Market capitalisation stands at Rs 23,077.25 crore.